 | By Lineus Medical Lineus Medical® is proud to announce the U.S. Food and Drug Administration (FDA) has cleared its flag ship product, SafeBreak® Vascular, for use on all vascular access lines including peripheral IV catheters, midlines, peripherally inserted central...
|
 | By Lineus Medical Health Canada has issued a licence on Lineus Medical's flag ship product, SafeBreak® Vascular, for use on all vascular access lines including peripheral IV catheters, peripherally inserted central catheters, central venous catheters, midlines, IV ports,..
|
 | By Lineus Medical Lineus Medical, a medical device company focused on reducing IV complications, announced that the company's flagship product, SafeBreak Vascular, has received clearance from the U.S. Food and Drug Administration (FDA) for use in pediatric patients.
|
 | By Lineus Medical Lineus Medical is proud to announce its selection into the 2023 Fuel Accelerator Program.
|
 | By Lineus Medical Provides the Opportunity to Sell SafeBreak® Vascular in International Markets
|
 | By Lineus Medical Lineus Medical announces publication of the randomized controlled trial performed at Colorado State University Veterinary Teaching Hospital in the Journal of the American Veterinary Medical Association.
|
 | By Lineus Medical Lineus Medical continues to expand its patent portfolio with the issuance of two new patents. The first issued patent was a Japanese Utility Patent (JP7095097) for SafeBreak® Vascular, a break-away medical device that helps protect peripheral IV lines.
|
By Lineus Medical Contract awarded for products that bring improvement to health care industry
|
